Videos

NJII Names BioCentriq as Cell & Gene Therapy Mfg. Center

Newark, NJ process development and clinical manufacturing facility for cell and gene therapies becomes first of its kind located on a U.S. university campus.

By: Kristin Brooks

Managing Editor, Contract Pharma



The Biopharma Division at NJII was established to help the industry overcome challenges they face as they develop the next wave of cell and gene therapies. BioCentriq is the name of the Cell and Gene Therapy Development Center (CGTDC) owned by NJII. It is a state-of-the-art process development and cGMP manufacturing center equipped with two GMP suites for cell & gene therapy clinical production and a cell & gene therapy process development pilot plant.  Read More here

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters